MGI Tech introduces VisiOmics, an innovative AI-enabled pathology solution at ECP 2026, showcasing advanced imaging and analysis tools.

MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies that drive innovation in life science, today announced the European launch of VisiOmics (PMIF-20RS), a fully automated multiplex immunofluorescence (mIF) staining and imaging system, at the 38th European Congress of Pathology (ECP 2026), held in Stockholm from 12 to 16 September 2026. MGI Launches VisiOmics in Europe.

MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies that drive innovation in life science, today announced the European launch of VisiOmics (PMIF-20RS), a fully automated multiplex immunofluorescence (mIF) staining and imaging system, at the 38th European Congress of Pathology (ECP 2026), held in Stockholm from 12 to 16 September 2026. Under the theme “From Tissue to Answer”, the launch anchors a comprehensive pathology portfolio spanning tissue and molecular pathology. Whether the question is asked of proteins in a tissue section or of nucleic acids in a sample, MGI’s platforms deliver an accurate answer with AI embedded at every step. VisiOmics (PMIF-20RS) is now commercially available in Europe VisiOmics (PMIF-20RS) is a fully automated mIF staining and imaging system that brings high-plex, automated tissue analysis within reach of routine laboratory workflows. VisiOmics enables multiplex detection of protein markers within a single tissue section, allowing researchers to characterize cell populations and investigate their spatial organization within the tissue microenvironment: More than 20-plex detection per run, expandable to more than 100 markers from a single tissue section via cyclic staining. Walk-away automation of the full staining-to-imaging workflow. AI-powered image analysis with FluoXpert Vision – including cell segmentation,...